Immune Diversity Is Rewriting Atherosclerosis Biology
Atherosclerotic cardiovascular disease remains a major cause of death worldwide, but the immunology behind plaque formation is no longer being viewed through a static lens. Atherosclerosis is increasingly understood as a lipid-driven chronic inflammatory disease in which immune cell populations do not behave as fixed categories; they shift, adapt, and acquire new functions as lesions evolve. This review places those functional transitions at the center of disease biology, tying immune heterogeneity to lesion initiation, necrotic core expansion, fibrous cap weakening, and thrombotic complications.
One sentence captures the core clinical message: plaque behavior depends on immune state, not just lipid burden.
That reframing matters because the same cell lineage can promote repair in one setting and accelerate rupture in another. A macrophage in an early lesion is not the same biological actor as a macrophage embedded in a lipid-rich, hypoxic plaque core. Likewise, T-cell and B-cell subsets can support inflammatory amplification, immune regulation, or maladaptive remodeling depending on the local vascular milieu. The review argues that understanding those shifts is essential if cardiovascular prevention is to move beyond broad risk reduction toward targeted immune intervention.
Macrophage Plasticity Drives Lesion Growth and Instability
Macrophages occupy a central position in atherogenesis because they are both responders to lipid accumulation and executors of plaque remodeling. Their phenotypic transitions are especially important in advanced disease, where macrophages adopt specialized lipid-handling states that influence foam cell formation, necrotic core development, and clearance of cellular debris. Once efferocytosis becomes impaired, apoptotic cells accumulate rather than being removed efficiently, and the plaque core becomes more inflamed, more lipid-rich, and more structurally fragile.
This is not a minor cellular detail. Ineffective clearance of dead cells enlarges the necrotic core and weakens the fibrous cap, creating the structural setup for rupture and thrombosis. In clinical terms, the difference between a stable plaque and a rupture-prone plaque can be determined by whether immune cells preserve tissue homeostasis or push the lesion toward disintegration. The review emphasizes that macrophage heterogeneity is not merely descriptive; it maps directly onto the biology of plaque vulnerability.
T Cells, B Cells, and Innate Cells Act in Context-Dependent Ways
The review also extends beyond macrophages to the broader immune ecosystem inside atherosclerotic lesions. Distinct T-cell subsets exert context-dependent effects, with some populations fueling inflammatory injury and others contributing to immune restraint. B-cell subsets are similarly not uniform in effect. Their role depends on local signaling networks, the stage of disease, and the cellular neighbors with which they interact.
Innate immune populations participate through parallel pathways, shaping inflammatory tone, lipid handling, and tissue remodeling. Their functional output is determined by the microenvironment in which they reside, including the balance of cytokines, chemokines, and metabolic stress signals within the plaque. In this setting, immune crosstalk becomes a mechanistic driver rather than a background feature. Cellular interactions help determine whether the lesion remains contained or progresses toward cap thinning and thrombosis.
Single-Cell Transcriptomics Is Exposing Hidden Plaque States
Recent single-cell transcriptomic methods have changed how immune diversity is mapped in cardiovascular tissue. Instead of treating plaques as collections of broad cell classes, these approaches reveal dynamic molecular programs that distinguish one immune state from another. The review uses this technology as a framework for showing how local molecular networks and intercellular signaling shape the plaque microenvironment.
Single-cell data matter because they can capture transitional states that traditional bulk assays miss. A plaque can contain immune cells with overlapping lineage markers but sharply different functional behavior, and those distinctions may explain why lesions in similar patients evolve differently. The same analytic shift also makes it possible to connect transcriptional programs with concrete structural outcomes, such as necrotic core enlargement, fibrous cap weakening, and thrombotic risk. In practical terms, the plaque is being redefined as a spatially organized immune organ rather than a passive lipid deposit.
Vascular Territory and Timing Influence Immune Behavior
Immune activity in atherosclerosis is not uniform across the arterial tree. The review stresses spatiotemporal variation across vascular territories, indicating that the immune microenvironment differs by location and likely by stage of lesion development. Coronary, carotid, and other vascular beds do not present the same structural constraints or inflammatory inputs, so the immune response is not expected to look identical everywhere.
These variations have direct implications for precision therapy. A treatment strategy that appears biologically sound in one vascular bed may not behave the same way in another if the resident immune populations, lipid exposure, and tissue architecture differ. Local differences in immune cell composition may also help explain why some plaques remain clinically silent while others become unstable and produce acute events. The biology is spatial as well as temporal.
Immune Checkpoints and Precision Immunomodulation Remain Unresolved Clinically
The review gives particular attention to immune checkpoint regulation and its clinical implications. Checkpoint pathways are attractive because they can influence immune activation at a level deeper than conventional anti-inflammatory approaches, yet their use in atherosclerosis remains constrained by safety and biologic complexity. In a disease where protective and harmful immune functions coexist, indiscriminate suppression could blunt beneficial surveillance or impair repair.
Precision immunomodulation is therefore presented as a therapeutic direction rather than a ready-made solution. The goal is to identify which immune subpopulation is pathogenic, which molecular pathway is driving the lesion, and which vascular context is most likely to respond. Such targeting would be more biologically coherent than broadly dampening immunity across all patients with ASCVD. It would also align treatment with the specific immune mechanisms operating inside the plaque.
Translation to the Clinic Still Depends on Better Biological Mapping
The biggest barrier is not the absence of immune targets; it is the difficulty of assigning each target to the right stage of disease and the right patient population. Atherosclerosis is heterogeneous at the cellular level, and the review makes clear that this heterogeneity complicates translation from bench to bedside. Precision therapy will require a deeper map of immune states, their temporal shifts, and their relationship to plaque morphology and thrombotic risk.
For now, the review supports a clear clinical direction: immune profiling should be treated as part of the mechanistic backbone of future cardiovascular therapy development. The field will need to define which cell states predict instability, which pathways govern defective efferocytosis, and which interventions can alter those states without causing harm. Until those questions are answered, the promise of precision immunotherapy in atherosclerosis remains biologically compelling but clinically unproven.